Moderna Inc. ($MRNA) Stock Forecast: Up 8.8% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its mRNA-based vaccines, notably the COVID-19 vaccine. The stock showed strong growth today, reflecting favorable market sentiment.

Why is Moderna Inc. going up?

MRNA stock is up 8.8% on Jan 22, 2025 18:05

• Moderna secured a substantial funding of $590 million for bird flu vaccine development, likely instilling confidence among investors regarding the company's future prospects.
• Collaboration with the Health and Human Services (HHS) to create mRNA-based pandemic influenza vaccines and advance clinical trials for various subtypes played a role in the positive market response.
• A recent commercial case of bird flu in Georgia underscored the critical need for vaccine development, highlighting the significance of Moderna's efforts in this field.
• Moderna's dedication to vaccine development and strategic partnerships in combating infectious diseases were driving forces behind the stock's uptrend in today's market.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday - Absci ( NASDAQ:ABSI ) , ARM Holdings ( NASDAQ:ARM )

U.S. stocks were higher, with the Dow Jones index gaining over 100 points on Wednesday. Shares of Seagate Technology Holdings plc STX rose sharply during Wednesday's session after the company reported second-quarter EPS and revenues above analyst estimates.

https://www.benzinga.com/25/01/43130999/seagate-posts-upbeat-earnings-joins-netflix-travelers-teledyne-technologies-and-other-big-stocks-moving-higher-on

Company News for Jan 22, 2025

Companies In The Article Are:MRNA, WBA, FITB and ...

https://www.zacks.com/stock/news/2401010/company-news-for-jan-22-2025

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine - Moderna ( NASDAQ:MRNA )

According to the latest data from the Centers for Disease Control and Prevention, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

https://www.benzinga.com/general/biotech/25/01/43117087/bird-flu-update-first-commercial-case-in-georgia-moderna-receives-590-million-to-develop-vaccine

Why Is Moderna Stock Trading Higher On Tuesday? - Moderna ( NASDAQ:MRNA )

Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get the Real Story Behind Every Major Earnings Report Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from ...

https://www.benzinga.com/general/biotech/25/01/43105845/why-is-moderna-stock-trading-higher-on-tuesday-2

3M, Netflix And 3 Stocks To Watch Heading Into Tuesday - D.R. Horton ( NYSE:DHI ) , 3M ( NYSE:MMM )

With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

https://www.benzinga.com/news/earnings/25/01/43089042/3m-netflix-and-3-stocks-to-watch-heading-into-tuesday

Trending Today

Worldcoin ($WLD) Crypto Forecast: Up 13.7% Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.5% Today

Solana ($SOL) Crypto Forecast: Up 5.9% Today

Schlumberger N.V. ($SLB) Stock Forecast: Down 5.1% Today

Amphenol Corporation ($APH) Stock Forecast: Up 7.5% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 7.2% Today

Arista Networks Inc. ($ANET) Stock Forecast: Up 6.9% Today

Edison International ($EIX) Stock Forecast: Down 5.1% Today

TRON ($TRX) Crypto Forecast: Up 5.8% Today

Netflix Inc. ($NFLX) Stock Forecast: Up 10.6% Today

Moderna Inc. Price History

07.00.2025 - MRNA Stock was up 7.3%

• Moderna stock saw a 4.0% increase in trading today.
• Speculation on a surge in acute respiratory illnesses in the United States by the CDC may have positively influenced investor sentiment towards Moderna due to its role in vaccine development.
• Despite some bearish options trading, the overall market response and anticipated demand for Moderna's offerings appeared to drive the bullish uptrend in the stock price.

07.00.2025 - MRNA Stock was up 7.8%

• Moderna (MRNA) experienced a strong bullish movement today amidst the following developments:
• The US recorded its first human death from the H5N1 bird flu virus, leading to a rally in vaccine stocks like Novavax (NVAX).
• High levels of respiratory illnesses reported by the CDC boosted the demand for vaccine-related companies.
• Financial giants showed bullish sentiment towards Moderna, with a majority of traders displaying optimism in options trading.
• The CDC's report on the rise in acute respiratory illnesses across the US likely contributed to the positive market sentiment towards Moderna.
• Despite lagging behind the overall market, Moderna's stock price saw a notable increase, indicating investor confidence in the company's future prospects.

18.11.2024 - MRNA Stock was down 6.1%

• Moderna's stock showed a decline, potentially linked to its removal from the Nasdaq-100 Index, prompting a decrease in investor confidence.
• The spotlight on Sanofi's vaccine candidates for COVID-19 and influenza with the Fast Track designation may have shifted investor focus from Moderna, impacting its stock negatively.
• Today's bearish movement in MRNA stock might have been influenced by the market response to Moderna's index removal and the positive developments related to Sanofi's vaccine candidates.

06.11.2024 - MRNA Stock was up 6.4%

• The positive sentiment surrounding Moderna's latest Covid-19 vaccine update possibly drove the stock's bullish movement, despite some reluctance among Hong Kong residents.
• Moderna's stock performance could have been influenced by its recent inclusion among the top 10 large-cap gainers last week, alongside companies like Rivian Automotive and Rocket Lab.
• Investor confidence in Moderna's ongoing success in the biotech industry, especially amidst global vaccination initiatives, likely played a role in today's strong stock performance.

26.10.2024 - MRNA Stock was down 5.5%

• Moderna's stock experienced a bearish movement today, possibly due to:
• Profit-taking by investors after a period of strong performance, as indicated by the bearish stance taken by significant traders in options trading.
• Concerns about the spread of a mutated bird flu case in California, which could increase the urgency for vaccine development and potentially impact Moderna's competitive position in the market.
• Market volatility and overall sentiment affecting biotech stocks, leading to a broader sell-off in the sector.

10.11.2024 - MRNA Stock was down 5.0%

• The downward trend in Moderna's stock price today may be linked to reports of hesitation among Hong Kong residents regarding the latest Covid-19 vaccine offered by the company. This apprehension could have sparked concerns among investors about the potential impact on Moderna's vaccine sales and revenue.
• Moreover, a shift in options trading activities towards a negative stance by affluent investors could have exacerbated the pessimistic sentiment surrounding Moderna's stock, contributing to the notable decline witnessed today.
• These combined factors likely influenced the bearish perspective on Moderna's stock, underscoring the significance of public perception and investor sentiment in shaping market dynamics, particularly within the pharmaceutical industry.

11.11.2024 - MRNA Stock was down 5.1%

• Investor focus may have shifted due to Novavax's announcement of a late-stage study on a COVID-19-flu combo and flu vaccines, potentially impacting Moderna's stock negatively.
• Options trading trends suggest a bearish sentiment from deep-pocketed investors towards Moderna, which could have contributed to the stock's decline.
• Market reaction indicates that investors are closely monitoring developments in the biotech and vaccine landscape, making them highly responsive to news affecting Moderna's competitive position.

15.00.2025 - MRNA Stock was up 5.7%

• Moderna stock saw a significant upward trend even after announcing a revision in its 2025 sales forecast.
• Market response could be due to investors focusing on anticipated revenue growth later in 2025.
• Positive market conditions for the day may have overshadowed concerns about Moderna's reduced sales forecast.
• Investors appear hopeful about Moderna's future prospects, driving the stock's rise despite the sales forecast adjustment.

22.00.2025 - MRNA Stock was up 6.9%

• Moderna's stock surged after receiving $590 million in funding from the U.S. government to develop a vaccine for the bird flu outbreak, signaling confidence in the company's capabilities.
• Advancements in clinical studies for up to five subtypes of pandemic influenza vaccines further boosted investor optimism, driving the stock price higher.
• The market's positive reaction reflects the potential impact of Moderna's developments in addressing public health crises, positioning the company as a key player in the fight against infectious diseases.

22.00.2025 - MRNA Stock was up 8.8%

• Moderna secured a substantial funding of $590 million for bird flu vaccine development, likely instilling confidence among investors regarding the company's future prospects.
• Collaboration with the Health and Human Services (HHS) to create mRNA-based pandemic influenza vaccines and advance clinical trials for various subtypes played a role in the positive market response.
• A recent commercial case of bird flu in Georgia underscored the critical need for vaccine development, highlighting the significance of Moderna's efforts in this field.
• Moderna's dedication to vaccine development and strategic partnerships in combating infectious diseases were driving forces behind the stock's uptrend in today's market.

08.00.2025 - MRNA Stock was down 5.3%

• Despite positive news related to vaccine stocks and the CDC's report on the first US bird-flu death, Moderna's stock experienced strong bearish movement.
• Although there was a significant increase in options activity, with a majority of traders adopting a bullish stance, it did not result in a sustained uptrend for Moderna's stock.
• The recent trend in earnings estimate revisions suggested no signs of further strength, leading to negative market reactions possibly driven by concerns regarding the company's future earnings potential.
• Investors might be exhibiting caution regarding Moderna's ability to seize opportunities in the current vaccine market amidst competition and market volatility triggered by the news of the first human bird flu death in the US.

13.00.2025 - MRNA Stock was up 5.2%

• Moderna demonstrated a strong bullish movement today despite revising its 2025 sales forecast downwards, showcasing resilience in the market.
• Investor interest in vaccine-related stocks, including Moderna, surged following reports of the first US bird-flu fatality, highlighting the company's expertise in vaccine innovation.
• The increase in Moderna's stock price is potentially influenced by positive investor sentiment and speculative trading rather than firm financial performance given the adjusted sales outlook.
• Notwithstanding the reduced sales forecast, Moderna's stock price saw a significant rise, suggesting that market mood and external factors may have driven today's bullish trend.